Amicus Therapeutics Inc is a global biotechnology company that aims to treat rare and orphan diseases. The company's strategy focuses on global capacity with an international infrastructure, late-stage product acquisition, and biologics manufacturing. Amicus leverages its pharmacological technology to develop treatments for human genetic diseases by targeting mutated proteins. The company utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products.
| Website: | www.amicusrx.com |
| Email: | info@amicusrx.co.uk |
| Main Phone: | +1 609 662-2000 |
| Address: | 1 Cedar Brook Drive |
| State: | NJ |
| City / Town: | Cranbury |
| Country: | USA |
| Postal Code: | 08512 |
| Exchange: | NSD |
| CEO: | John F. Crowley |
| Employees: | 508 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
When evaluating a biotech company, the backers often tell the tale...
Volatility is the nature of the biotech beast, and it must be tamed or utilized to advantage. That's the philosophy of Eden Rahim, portfolio manager and option strategist at Theta Strategies
Over the first six months of 2015, the market has not performed very well. Since the 1st of the year, the DJIA has essentially remained the same (down 0.4% to be exact). The S&P 500 has also
Stocks were trading higher on Tuesday as all the major indices posted significant gains, with the Nasdaq leading the charge. Among the day’s big gainers were growth companies and biotechs,
Shares in Amicus Therapeutics (FOLD) spiked on Tuesday following the news that its lead therapy, climbing over 20 percent after reporting success in Phase III trials of migalastat HCL in
At www.ValuEngine.com we show that the Medical sector 10.6% overvalued with the Medical Biomed / Genetics 12.3% overvalued. All 16 stocks in today’s table have complete ValuEngine data and have
After missing earlier this month on achieving a statistically significant response in a phase 3 study with partner GlaxoSmithKline (GSK) for migalastat HCl against Fabry disease that chopped their
Initial Jobless Claims were higher than expected in the latest week at 428,000. Remember that the Recessionary Threshold is 350,000. The Chicago PMI rose to a stronger than expected reading of
Gathering Data... Please wait Amicus Therapeutics Inc is a global biotechnology company that aims to treat rare and orphan diseases. The company's strategy focuses on global capacity with an international infrastructure, late-stage product acquisition, and biologics manufacturing. Amicus leverages its pharmacological technology to develop treatments for human genetic diseases by targeting mutated proteins. The company utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products.
| Website: | www.amicusrx.com |
| Email: | info@amicusrx.co.uk |
| Main Phone: | +1 609 662-2000 |
| Address: | 1 Cedar Brook Drive |
| State: | NJ |
| City / Town: | Cranbury |
| Country: | USA |
| Postal Code: | 08512 |
| Exchange: | NSD |
| CEO: | John F. Crowley |
| Employees: | 508 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
When evaluating a biotech company, the backers often tell the tale...
Volatility is the nature of the biotech beast, and it must be tamed or utilized to advantage. That's the philosophy of Eden Rahim, portfolio manager and option strategist at Theta Strategies
Over the first six months of 2015, the market has not performed very well. Since the 1st of the year, the DJIA has essentially remained the same (down 0.4% to be exact). The S&P 500 has also
Stocks were trading higher on Tuesday as all the major indices posted significant gains, with the Nasdaq leading the charge. Among the day’s big gainers were growth companies and biotechs,
Shares in Amicus Therapeutics (FOLD) spiked on Tuesday following the news that its lead therapy, climbing over 20 percent after reporting success in Phase III trials of migalastat HCL in
At www.ValuEngine.com we show that the Medical sector 10.6% overvalued with the Medical Biomed / Genetics 12.3% overvalued. All 16 stocks in today’s table have complete ValuEngine data and have
After missing earlier this month on achieving a statistically significant response in a phase 3 study with partner GlaxoSmithKline (GSK) for migalastat HCl against Fabry disease that chopped their
Initial Jobless Claims were higher than expected in the latest week at 428,000. Remember that the Recessionary Threshold is 350,000. The Chicago PMI rose to a stronger than expected reading of
| Last Price 8.14 | Change $ 0.28 | Change % 3.56 | Tick N/A |
| Bid 8.13 | Bid Size 400.00 | Ask 8.14 | Ask Size 2,300.00 |
| Open 7.84 | High 8.17 | Low 7.80 | Prev Close 7.86 |
| Last Trade | Volume 764,350 | 52 Wk Hi 14.62 | 52 Wk Low 7.11 |
| Market Cap 2.1 bi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 254,626,063.00 | EPS (TTM) -2.17 | PE Ratio N/A | Exchange NSD |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 22 | 110 |
| Number of Buys | 13 | 61 |
| Number of Sells | 9 | 49 |
| Net Activity | -78433 | 2199222 |
| Last 10 Buys | Shares |
|---|---|
| Edelman Joseph | 1,000 |
| Edelman Joseph | 1,000 |
| Edelman Joseph | 1,000 |
| Edelman Joseph | 1,000 |
| Ellen S. Rosenberg | 1,000 |
| Margaret G. McGlynn | 1,000 |
| Edelman Joseph | 1,000 |
| Edelman Joseph | 1,000 |
| Edelman Joseph | 1,000 |
| Edelman Joseph | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Hung Do | 1,000 |
| Hung Do | 1,000 |
| Margaret G. McGlynn | 1,000 |
| Jay Barth | 1,000 |
| Hung Do | 1,000 |
| Michael G. Raab | 1,000 |
| Jay Barth | 1,000 |
| Kurt J. Andrews | 1,000 |
| William D. Baird | 1,000 |
| Jay Barth | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 22 | 22 | 22 | 22 |
| Low Target Price Estimate | 18.5 | 18.5 | 18.5 | 18.5 |
| Mean Target Price Estimate | 20.08 | 20.08 | 20.08 | 20.08 |
| Standard Deviation | 1.56 | 1.56 | 1.56 | 1.56 |
| Date of Most Recent Estimate | 05/11/18 | 05/11/18 | 05/11/18 | 05/11/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-11 |
| 8-K | Report of unscheduled material events or corporate changes. | 21 | 2018-06-08 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-04 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-18 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1 | 1 | 1 | 1 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
